173,288 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Acquired by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 173,288 shares of the company's stock, valued at approximately $10,848,000. Vestmark Advisory Solutions Inc. owned 0.22% of CRISPR Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. CWM LLC grew its stake in CRISPR Therapeutics by 80.7% in the 3rd quarter. CWM LLC now owns 582 shares of the company's stock valued at $26,000 after acquiring an additional 260 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in shares of CRISPR Therapeutics by 21.7% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 33,378 shares of the company's stock worth $1,515,000 after purchasing an additional 5,948 shares in the last quarter. Stratos Wealth Partners LTD. raised its position in shares of CRISPR Therapeutics by 28.2% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 5,580 shares of the company's stock worth $253,000 after purchasing an additional 1,226 shares during the last quarter. Stratos Wealth Advisors LLC raised its position in shares of CRISPR Therapeutics by 86.1% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 10,561 shares of the company's stock worth $479,000 after purchasing an additional 4,886 shares during the last quarter. Finally, Independent Advisor Alliance lifted its stake in CRISPR Therapeutics by 327.2% in the 3rd quarter. Independent Advisor Alliance now owns 15,256 shares of the company's stock valued at $692,000 after buying an additional 11,685 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded up $0.82 during trading hours on Friday, hitting $55.89. The company's stock had a trading volume of 1,426,901 shares, compared to its average volume of 1,308,278. The firm has a fifty day moving average of $67.75 and a 200-day moving average of $64.48. The stock has a market cap of $4.74 billion, a price-to-earnings ratio of -28.52 and a beta of 1.80. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to analysts' expectations of $148.72 million. The business's revenue for the quarter was up 3253.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.41) EPS. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the sale, the chief executive officer now owns 187,377 shares of the company's stock, valued at $15,057,615.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the sale, the chief executive officer now directly owns 187,377 shares in the company, valued at $15,057,615.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 2,801 shares of CRISPR Therapeutics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $78.26, for a total value of $219,206.26. Following the completion of the transaction, the general counsel now owns 60,070 shares of the company's stock, valued at $4,701,078.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 83,992 shares of company stock worth $6,132,335. 4.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Barclays increased their target price on CRISPR Therapeutics from $61.00 to $80.00 and gave the company an "equal weight" rating in a report on Thursday, February 22nd. Wolfe Research began coverage on CRISPR Therapeutics in a report on Thursday, February 15th. They issued a "peer perform" rating on the stock. Royal Bank of Canada upped their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a "sector perform" rating in a report on Thursday, February 22nd. Mizuho increased their target price on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a "buy" rating in a research report on Wednesday, March 6th. Finally, Chardan Capital boosted their price target on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a "buy" rating in a research report on Thursday, February 22nd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics presently has an average rating of "Hold" and a consensus target price of $76.29.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.